Anal, Rectal (e.g., Suppositories, Etc.) Patents (Class 424/436)
  • Patent number: 5283064
    Abstract: A large intestinal dissociative hard capsule comprising a capsule mainly composed of chitosan, the viscosity at 20.degree. C. of a solution obtained by dissolving the chitosan in an aqueous 1% by weight acetic acid solution being not higher than 100 cps and the degree of deacetilation of the chitosan being from 60 mol % to 98 mol %, having a coated layer of a polymer soluble in a liquid having pH of at least 5 on the surface of the capsule.
    Type: Grant
    Filed: June 4, 1991
    Date of Patent: February 1, 1994
    Assignee: Aicello Chemical Co., Ltd.
    Inventors: Tsutomu Suzuki, Kenichi Hashiudo, Takayuki Matsumoto, Toshihiro Higashide, Takeru Fujii
  • Patent number: 5281711
    Abstract: The compound (S)-1-[(10-chloro-6,7-dihydro-4-oxo-3-phenyl-4H-benzo[a]quino-lizin-1-yl)c arbonyl]-3-ethoxypyrrolidine of the formula ##STR1## which has valuable pharmacological properties, is described. In particular, the compound of formula I has a non-sedating, hypnotic, that is, sleep-promoting, activity and can accordingly be used for the treatment of sleep disorders.
    Type: Grant
    Filed: January 6, 1992
    Date of Patent: January 25, 1994
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Richard R. Scherschlicht, Ulrich Widmer
  • Patent number: 5275820
    Abstract: Sustained release pharmaceutical compound delivery compositions and methods for their production are disclosed wherein ion exchange resin particles are loaded with releasably bound pharmaceutical compounds prior to incorporation in an erodible polymeric matrix to form microparticulates. The microparticulates are suspended in a fluid medium where the encapsulating polymeric matrix shields the drug loaded ion exchange resin from solvent interaction. Administration to a target tissue site initiations erosion of the polymer matrix and release of the loaded pharmaceutical compound.
    Type: Grant
    Filed: December 27, 1990
    Date of Patent: January 4, 1994
    Assignee: Allergan, Inc.
    Inventor: Nienyuan J. Chang
  • Patent number: 5244668
    Abstract: An excipient for a pharmaceutical compound which melts at body temperature but will not spontaneously deform at higher temperatures encountered in shipment and storage comprises:______________________________________ Low MW Polyethylene glycol 75-90% (M.P. about 37.degree. C.) Medium to high MW polyethylene glycol 0-4% Long chain saturated carboxylic acid 0-4% Polyethylene oxide 0-4% (MW 100,000-5,000,000) Colloidal silica 10-20%. ______________________________________The excipient is particularly advantageous for the preparation of dosage forms for buccal administration of pharmaceutical compounds.
    Type: Grant
    Filed: August 17, 1992
    Date of Patent: September 14, 1993
    Assignee: Zetachron, Inc.
    Inventor: Wallace C. Snipes
  • Patent number: 5240700
    Abstract: A composition for inhibiting the degeneration of cells including liver cells by drugs and relieving the toxicity of drugs to internal organs including the liver contains as an essential component a 3-oxygermylpropionic acid polymer which is represented by:[(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH].sub.nwherein n is an integer of at least 1, takes the form of a white acicular crystal and has a melting point of about 230.degree. C. at which it decomposes or coagulates. The present composition may be used with a carrier hydroxypropylcellulose in an amount of 0.005 to 50% by weight relative to 0.005 to 5% by weight of the 3-oxygermylpropionic acid polymer.
    Type: Grant
    Filed: May 7, 1992
    Date of Patent: August 31, 1993
    Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.
    Inventors: Kiichi Sawai, Masayasu Kurono, Kazumasa Nakano, Kyoichi Asano, Takahiko Mitani, Naohisa Ninomiya, Bunkichi Kato
  • Patent number: 5219870
    Abstract: This invention relates to omeprazole compositions designed for administration in the rectum, wherein said compositions comprise omeprazole, an active ingredient, a mixture of polyethylene glycols having molecular weights 1,000, 1,540, 4,000 and/or 6,000 or a mixture of adeps solidus and sodium laurylsulfate and a soluble, basic amino acid selected from arginine, lysine or histidine.
    Type: Grant
    Filed: February 27, 1991
    Date of Patent: June 15, 1993
    Inventor: Kwang Sik Kim
  • Patent number: 5215758
    Abstract: The controlled release of therapeutically active agents is achieved from a controlled release matrix of sodium alginate and a calcium salt. When the composition is to be administered rectally, the matrix is combined with a therapeutically active agent and a suitable suppository base. When the composition is to be administered orally, the matrix further includes a higher aliphatic alcohol.
    Type: Grant
    Filed: September 11, 1991
    Date of Patent: June 1, 1993
    Assignee: Euroceltique, S.A.
    Inventor: Thinnayam N. Krishnamurthy
  • Patent number: 5213803
    Abstract: A method utilizing compositions for topical application which are adapted for the prevention and treatment of viral infections such as Herpes, AIDS and other envelope virus infections are disclosed. The compositions of the present invention produce a synergistic anti-viral effect when used in combination. The formulation contains a humectant such as sorbitol, glycerol, or other comparable compound in the range of 20-80% w/v final concentration, which facilitates structural and/or functional three dimensional disruption or disorientation of the viral envelope. The activation of the destruction of the envelope and subsequent death of the envelope virus is then achieved using combination of inorganic monovalent anions, nonionic detergents and anionic detergents. These monovalent anions can include sodium bicarbonate, sodium thiocyanate, sodium fluoride and sodium chloride at about 0.5 to 5% w/v final concentration; nonionic detergents such as Tween 20 at concentrations of about 0.
    Type: Grant
    Filed: February 24, 1992
    Date of Patent: May 25, 1993
    Assignee: Northeastern Ohio Universities College of Medicine
    Inventors: Jerry J. Pollock, John J. Docherty
  • Patent number: 5213802
    Abstract: Pharmaceutical formulations employing novel non-allergenic, non-irritating, non-toxic, and non-digestible carriers, bases, or vehicles for topical or ingestible drug delivery are disclosed. The carriers are esterified alkoxylated polyols; preferred carrier embodiments include propoxylated glycerols which are esterified with C.sub.8 -C.sub.24 fatty acids. The non-digestibility of the esterified alkoxylated polyols permits, for example, delivery of medicaments taken orally directly to the lower gastrointestinal tract.
    Type: Grant
    Filed: September 24, 1990
    Date of Patent: May 25, 1993
    Assignee: Arco Chemical Technology, L.P.
    Inventor: Lawrence W. Masten
  • Patent number: 5206008
    Abstract: The present invention provides an improved means for regulating the immune response, for ameliorating effects of stress, and for avoiding untoward effects of chemotherapy or exposure to irradiation by administration of androstenediol (AED) and androstenetriol (AET). The improved means of regulating immune response can be utilized in treating infectious diseases and immune diseases such as diabetes and chronic fatigue syndrome, both diseases now considered to be immune response related syndromes.
    Type: Grant
    Filed: August 2, 1991
    Date of Patent: April 27, 1993
    Assignee: Virginia Commonwealth University
    Inventor: Roger Loria
  • Patent number: 5206029
    Abstract: The present invention provides a medicament for the treatment of painful and/or inflammatory diseases and/or of fever with flurbiprofen, wherein the previously separated enantiomers of flurbiprofen are worked up in a ratio of 99.5-0.5% to 0.5-99.5%, in combination with conventional pharmaceutical carriers and adjuvants, to give a medicament.
    Type: Grant
    Filed: May 16, 1991
    Date of Patent: April 27, 1993
    Assignee: PAZ Arzneimittel-Entwicklungsgesellschaft mbH
    Inventors: Gerd Geisslinger, Kay Brune
  • Patent number: 5204108
    Abstract: A drug delivery composition comprising a plurality of microspheres and active drug associated with each microsphere, the drug being for systemic delivery and having a maximum molecular weight of 6000, and the composition being substantially free of an enhancer. The microspheres may be of starch, gelatin or albumin. Suitable drugs include peptides, such as insulin, and antigenic vaccine ingredients. The compositions are suitable for delivery across a mucosal surface such as the vagina, eye or nose.
    Type: Grant
    Filed: April 9, 1990
    Date of Patent: April 20, 1993
    Assignee: Danbiosyst UK Ltd.
    Inventor: Lisbeth Illum
  • Patent number: 5200198
    Abstract: The present invention provides a medicament for the treatment of painful and/or inflammatory diseases and/or of fever with flurbiprofen, wherein the flurbiprofen is pure or preponderantly R(-)-flurbiprofen worked up in combination with conventional pharmaceutical carriers and adjuvants, to give a medicament.
    Type: Grant
    Filed: May 16, 1991
    Date of Patent: April 6, 1993
    Assignee: Paz Arzneimittel-Entwicklungsgesellschaft mbH
    Inventors: Gerd Geisslinger, Kay Brune
  • Patent number: 5192802
    Abstract: Bioadhesive pharmaceutical carrier consisting essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate. The invention also provides for a method of control releasing a pharmaceutical active comprising incorporating an active into the bioadhesive pharmaceutical carrier. The invention is particularly adaptable for oral use and teething gels.
    Type: Grant
    Filed: September 25, 1991
    Date of Patent: March 9, 1993
    Assignee: McNeil-PPC, Inc.
    Inventor: William F. Rencher
  • Patent number: 5178873
    Abstract: A method of inhibiting phospholipase A2 in the control of inflammation, wherein delta-6,9,12,15-octadecatetraenoic acid (stearidonic acid) and/or delta-8,11,14,17-eicosatetraenoic acid is administered alone or in a pharmaceutically acceptable diluent or carrier.
    Type: Grant
    Filed: May 23, 1991
    Date of Patent: January 12, 1993
    Assignee: Efamol Holdings PLC
    Inventors: David F. Horrobin, Michael J. Finnen
  • Patent number: 5167949
    Abstract: The present invention relates to 4(3H)-pteridinones represented by the formula: ##STR1## in which X is an oxygen atom or a sulphur atom, Y is a hydrogen atom, a lower alkyl radical, especially a methyl radical, at the 6-position or a hydroxyl group at the 7-position, R.sub.1 is a hydrogen atom, a lower alkyl radical, a substituted or unsubstituted phenyl radical, a benzyl radical, a methoxymethyl group, an acetyl group, a 2-acetoxyethyl group or a 2,2,2-trifluoroethyl group and R.sub.2 is a hydrogen atom or a lower alkyl radical, especially a methyl radical. Application of these compounds as anti-allergic drugs.
    Type: Grant
    Filed: March 29, 1990
    Date of Patent: December 1, 1992
    Assignee: Lipha, Lyonnaise Industrielle Pharmaceutique
    Inventors: Gerard Ferrand, Herve Dumas, Jean-Claude Depin, Yvette Quentin
  • Patent number: 5167963
    Abstract: 8,10-Dideazatetrahydrofolic acid derivatives of the formula: ##STR1## where R.sub.1 and R.sub.2 are selected from hydrogen and alkyl having from one to about eight carbon atoms and the carboxylates and acid addition salts thereof, showing strong inhibition of L1210 murine leukemia cells in culture, modest inhibition of glycinamide ribotide transformylase and aminoimidazole carboxamide ribotide transferase, and insignificant inhibition of dihydrofolate reductase and thymidylate synthase enzymes.
    Type: Grant
    Filed: July 27, 1990
    Date of Patent: December 1, 1992
    Assignees: SRI International, Sloan-Kettering Institute for Cancer Research
    Inventors: Joseph I. DeGraw, William T. Colwell, Francis M. Sirotnak
  • Patent number: 5152994
    Abstract: The administration to a poly-drug addict of ibogaine, ibogaine, tabernanthine, alkaloids in the family of apocynaceae, or their non-toxic salts have been discovered to interrupt the physiological and psychological aspects of poly-drug dependency (heroin, cocaine, alcohol, nicotine, caffeine, amphetamine, desoxyephedrine or methadone in combinations thereof). A single treatment or series of treatments may be effective for one to eighteen months or longer. Treatment consists of the oral or rectal administration of ibogaine, ibogamine, tabernanthine or their salts or derivatives in dosage ranges of 1 mg/kg to 60 mg/kg.
    Type: Grant
    Filed: May 31, 1990
    Date of Patent: October 6, 1992
    Inventor: Howard S. Lotsof
  • Patent number: 5149537
    Abstract: Suppositories comprising a suppository base, a calcitonin and taurocholic acid or a pharmaceutically acceptable salt thereof exhibit improved bioavailability and are well tolerated.
    Type: Grant
    Filed: November 14, 1991
    Date of Patent: September 22, 1992
    Assignee: Sandoz Ltd.
    Inventors: Moise Azria, Michel Steiger
  • Patent number: 5143731
    Abstract: Balanced pH, thermo-irreversible gels are ideal vehicles for drug delivery to a body cavity of a mammal. The gels contain a mixture of a polyoxyalkylene block copolymer or polyether together with an ionic polysaccharide which is thermo-irreversibly gelled in the presence of a counter-ion.
    Type: Grant
    Filed: August 7, 1990
    Date of Patent: September 1, 1992
    Assignee: Mediventures Incorporated
    Inventors: Tacey X. Viegas, Lorraine E. Reeve, Raymond L. Henry
  • Patent number: 5139790
    Abstract: An excipient for a pharmaceutical compound which melts at body temperature but will not spontaneously deform at higher temperatures encountered in shipment and storage comprises:______________________________________ Low MW Polyethylene glycol 75-90% (M.P. about 37.degree. C.) Medium to high MW polyethylene glycol 0-4% Long chain saturated carboxylic acid 0-4% Polyethylene oxide 0-4% (MW 100,000-5,000,000) Colloidal silica 10-20%. ______________________________________The excipient is particularly advantageous for the preparation of dosage forms for buccal administration of pharmaceutical compounds.
    Type: Grant
    Filed: March 29, 1991
    Date of Patent: August 18, 1992
    Assignee: Zetachron, Inc.
    Inventor: Wallace C. Snipes
  • Patent number: 5137724
    Abstract: The antiviral activity of 5-fluoro-uracil, 5-fluoro-2'-deoxyuridine and similar thymilydate synthetase inhibitors towards herpes viruses can be potentiated dramatically by combining these compounds with compounds having viral thymidine kinase inhibiting activity.
    Type: Grant
    Filed: July 22, 1991
    Date of Patent: August 11, 1992
    Assignee: Stichting Rega VZW
    Inventors: Jan M. R. Balzarini, Erik D. A. De Clercq
  • Patent number: 5122598
    Abstract: New polysaccharide esters are disclosed, and more precisely esters of acidic polysaccharides chosen from the group formed by carboxymethylcellulose, carboxymethyl starch and carboxymethylchitin. These new esters and some esters of the type already known are useful as medicaments, for the manufacture of pharmaceutical and cosmetic preparations, in the field of biodegradable plastic materials and, therefore, for the manufacture of medical, surgical and sanitary articles, as well as numerous other industrial sectors in the place of acidic polysaccharides now in common use.
    Type: Grant
    Filed: May 12, 1989
    Date of Patent: June 16, 1992
    Assignee: Fidia S.p.A.
    Inventors: Francesco della Valle, Aurelio Romeo
  • Patent number: 5110605
    Abstract: A polymeric complex composition comprising a reaction complex formed by the interaction of a polycarbophil component with alginic acid or a salt thereof, said interaction being performed in the presence of a divalent cation and in the presence of an active agent selected from the group consisting of medicinal agents and cosmetic agents. There is also described a method of controlled release treatment comprising the steps of providing such a polymeric complex and an effective amount of an active agent selected from the group consisting of medicinal agents and cosmetic agents contained within said complex, and contacting an area of skin or mucous membrane to be treated with said composition for a sufficient period of time allow a therapeutically effective amount of said active agent to be released from the complex.
    Type: Grant
    Filed: August 21, 1990
    Date of Patent: May 5, 1992
    Assignee: Oramed, Inc.
    Inventor: Ramesh N. Acharya
  • Patent number: 5102667
    Abstract: This invention relates to isoindolone derivatives of general formula (I) in which the radicals R are hydrogen atoms or together form a bond, the symbols R' are phenyl radicals which can be substituted by a halogen atom or a methyl radical in position 2 or 3, X is an oxygen or sulphur atom or a radical N--R.sub.3, R.sub.3 being H, optionally substituted alkyl or dialkylamino, R.sub.1 is optionally substituted phenyl or cyclohexadienyl, naphthyl or a heterocycle and R.sub.2 is H, halogen, OH, alkyl, amionoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, alkylthio, acyloxy, carboxyl, optionally substituted alkoxycarbonyl, benzyloxycarbonyl, amino or acylamino, in their (3aR,7aR) forms or in the (3aRS,7aRS) form or their mixtures, and if appropriate their salts where such exist, and their preparation.The new derivatives according to the invention are particularly valuable as antagonists of substance P.
    Type: Grant
    Filed: November 20, 1990
    Date of Patent: April 7, 1992
    Assignee: Rhone-Poulenc Sante
    Inventors: Marie-Christine Dubroeucq, Claude Moutonnier, Jean-Francois Peyronel, Michel Tabart, Alain Truchon
  • Patent number: 5093127
    Abstract: A cyclic peptide designated FR115224, administered parenterally in a cyclodextrin carrier, which exhibits antiallergic activity.
    Type: Grant
    Filed: May 18, 1990
    Date of Patent: March 3, 1992
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Sotoo Asakura, Nobuto Kanagawa, Kiyota Youhei
  • Patent number: 5079009
    Abstract: A controlled release composition comprising an active substance other than a prostaglandin and a polymeric carrier therefor comprising residues having a ratio of number average molecular weight to functionality greater than 1000 which comprises polyethylene oxide and are cross-linked through urethane groups.
    Type: Grant
    Filed: January 2, 1990
    Date of Patent: January 7, 1992
    Assignee: National Research Development Corporation
    Inventors: Mostyn P. Embrey, Neil B. Graham
  • Patent number: 5079006
    Abstract: A pharmaceutical preparation is provided for oral or anal administration containing, in addition to a selected pharmacologically active agent, at least one magnetic material capable of reacting to an externally acting magnetic field of an electronic monitoring device, so that after administration to a patient, a signal is produced that is selectively detectable by such a monitoring device, thus providing information on whether the preparation has been taken or not by the patient and/or facilitates locating the preparation or the magnetic material in the region of the gastrointestinal tract of the patient.
    Type: Grant
    Filed: July 13, 1988
    Date of Patent: January 7, 1992
    Assignee: Aprex Corporation
    Inventor: John Urquhart
  • Patent number: 5075112
    Abstract: Method of, and dosage unit for, inhibiting angiogenesis in an aminal having an intestinal wall by administering to the animal, orally or anally, an effective amount of shark cartilage, particularly finely divided shark cartilage in solid dosage form such as a tablet, capsule, suppository, for passing through the intestinal wall of the animal as a suspension.
    Type: Grant
    Filed: February 12, 1990
    Date of Patent: December 24, 1991
    Assignee: Cartilage Technologies Inc.
    Inventor: Irwin W. Lane
  • Patent number: 5070107
    Abstract: Systemic antiviral treatment using a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 27 to 32 carbons in the chain in physiologically compatible compositions for injection or trans-mucus membrance introduction into humans and other mammals is disclosed.
    Type: Grant
    Filed: November 2, 1989
    Date of Patent: December 3, 1991
    Assignee: Lidak Pharmaceuticals
    Inventor: David H. Katz
  • Patent number: 5063060
    Abstract: The invention relates to a method of treating painful, inflammatory or allergic disorders comprising treatment with an effective amount of a composition comprising cis-8-methyl-N-vanillyl-6-nonenamide. The invention also relates to compositions for use in the inventive method.
    Type: Grant
    Filed: December 19, 1989
    Date of Patent: November 5, 1991
    Assignee: Cisco Limited Partnership
    Inventor: Joel E. Bernstein
  • Patent number: 5055303
    Abstract: Solid delivery systems which at body temperature exhibit controlled release and bioadherence characteristics. These systems are emulsions which are water in oil in nature and whose internal phase is greater than that of the external phase. That is, the internal phase comprises at least 60% of the system.
    Type: Grant
    Filed: January 31, 1989
    Date of Patent: October 8, 1991
    Assignee: KV Pharmaceutical Company
    Inventor: Thomas C. Riley, Jr.
  • Patent number: 5055301
    Abstract: The invention relates to the use of dextran sulphate, optionally in combination with anti-androgen agents, for the treatment of the human prostatic carcinoma. Inhibition of the growth of both androgen-dependent and androgen-independent carcinoma cells is achieved according to the invention. The invention therefore leads to a significant improvement in the possible therapies for human prostatic carcinoma.
    Type: Grant
    Filed: January 17, 1990
    Date of Patent: October 8, 1991
    Assignee: Entec Gesellschaft fur Endokrinologische Technologie m.b.H.
    Inventors: Klaus-Dieter Voigt, Cornelius Knabbe
  • Patent number: 5045316
    Abstract: Pharmaceutically active combination comprising an ionic vanadium compound and thiosulphate or sulfite compound and optionally selenium, pharmaceutical compositions containing same and method for treating malignant tumors, arteriosclerosis and mental syndromes in the elderly.
    Type: Grant
    Filed: December 21, 1987
    Date of Patent: September 3, 1991
    Inventor: Ephraim Kaplan
  • Patent number: 5039667
    Abstract: A method is disclosed for the treatment of hepadnavirus infection in animals. Animals infected with duck hepatitis B virus may be treated with the 2',3'-dideoxynucleoside of adenine, guanine, hypoxanthine, 2,6-diaminopurine or various analogs of substituted purines. Several purine 2',3'-dideoxynucleosides inhibit duck hepatitis B virus in hepatocyte culture >99% at 1 .mu.g/ml. Potent in vivo efficacy of the 2,6-diaminopurine 2',3'-dideoxynucleoside for clearance of duck hepatitis B virus from the sera of Pekin ducks is demonstrated. The selective effect on hepadnavirus replication by the purine 2',3'-dideoxynucleosides is based on the discovery of an unexpected sensitivity of hepadnavirus to purine 2',3'-dideoxynucleoside analogs. These compounds present a new antiviral therapy of acute or persistent hepadnavirus infections.
    Type: Grant
    Filed: August 5, 1988
    Date of Patent: August 13, 1991
    Assignee: The Governors of the University of Alberta
    Inventors: David L. J. Tyrrell, Morris J. Robins, Satoru Suzuki
  • Patent number: 5035884
    Abstract: A new series of copolymers which are useful as coatings for solid dosage forms, for transdermal devices, for wound dressing materials, and for contact lenses. Also disclosed are methods for preparing monomers and polymers as well as pharmaceutical compositions containing such polymers.
    Type: Grant
    Filed: February 15, 1990
    Date of Patent: July 30, 1991
    Assignee: Warner-Lambert Company
    Inventors: Suk-Zu Song, Surendra C. Mehta, Kuchi S. Murthy, Russell U. Nesbitt, Mahdi B. Fawzi
  • Patent number: 5021242
    Abstract: The invention is related to solid drug preparations of 2-phenyl-1,2-benzisoselenazol-3(2H)-one (EBSELEN) with high bioavailability comprising EBSELEN in the form of micronized crystals, and a method of manufacturing the same.
    Type: Grant
    Filed: June 20, 1988
    Date of Patent: June 4, 1991
    Assignee: A. Nattermann & Cie GmbH
    Inventors: Axel Romer, Jurgen Seidel
  • Patent number: 5017382
    Abstract: A process for the preparation of a controlled release composition comprising a prostaglandin and a polymeric carrier therefor comprising residues having a ratio of number average molecular weight to functionality greater than 1,000 which comprise polyethylene oxide and are cross-linked through urethane groups.
    Type: Grant
    Filed: January 23, 1990
    Date of Patent: May 21, 1991
    Assignee: National Research Development Corporation
    Inventors: Mostyn P. Embrey, Neil B. Graham
  • Patent number: 5015474
    Abstract: Methods and compositions are provided for alleviating the dryness of a dermal or mucosal membrane substrate. The compositions are formulated from eriodictyon fluid which is a Yerba Santa extract and viscous excipients, and may be in the form of an aqueous vaginal douche, a cream or a suppository. The compositions may additionally contain a lubricant compound effective to provide lubrication and relieve frictional irritation on the affected area. Preservatives, topical anesthetics, coloring agents, emulsifiers, and the like may be included in the compositions as well. The Yerba Santa-based compositions of the invention are topically administered to an affected patient to alleviate the symptoms of dryness.
    Type: Grant
    Filed: March 26, 1990
    Date of Patent: May 14, 1991
    Assignee: Parnell Pharmaceuticals, Inc.
    Inventor: Francis W. Parnell
  • Patent number: 4997643
    Abstract: A biocompatible, film-forming delivery system for the delivery of pharmaceutical or therapeutic actives to a desired topical site of a subject, the system including:an active salt compound, wherein the active salt compound is at least a partial salt of(1) a carboxylic acid moiety-containing, biocompatible, film-forming polymer with(2) at least one active selected from the group consisting of pharmaceutical actives, therapeutic actives and a combination thereof, wherein the at least one active is capable of complexing with at least one carboxylic acid moiety of the polymer to form the active salt compound, andwherein the active salt compound forms an active salt compound film on the topical site and the active salt compound disassociates into the polymer and the at least one active while the delivery system is in contact with the topical site such that the polymer remains thereon as a polymer film and the at least one active is delivered to the topical site in an absorbable form.
    Type: Grant
    Filed: July 12, 1989
    Date of Patent: March 5, 1991
    Assignee: Union Carbide Chemicals and Plastics Company Inc.
    Inventors: Emmett M. Partain, III, George L. Brode, II
  • Patent number: 4994275
    Abstract: Device for oral administration of a medicament to a ruminant animal comprises a rilaminate sheet (1) containing the medicament rolled into a tube retained in the rolled configuration by a film (3) of material which disintegrates in the rumen to allow unrolling of the sheet. The tube ends are closed by plugs (2) which keep the tube closed during passage of the device through the oesophagus.
    Type: Grant
    Filed: June 26, 1989
    Date of Patent: February 19, 1991
    Assignee: Pfizer Inc.
    Inventors: William T. R. Grimshaw, Andrew J. Weatherley
  • Patent number: 4990529
    Abstract: 2-Pyrazoline derivatives of the formula (A): ##STR1## where R.sup.1 is a pyridyl, a pyrazyl or an alkoxyl group; and R.sup.2 is a hydrogen atom, an alkyl, a pyridyl, a furyl, phenyl or a substituted phenyl group, and to a process for producing the same. Therapeutic agents for treating cerebrovascular diseases containing, as the active ingredient, a 2-pyrazoline derivative represented by the formula (G): ##STR2## where R.sup.3 is a hydrogen atom, an alkyl, acetyl, an alkoxycarbonyl, an amino, benzoyl, a substituted benzoyl, a pyridylcarbonyl, a furylcabonyl, a thienylcarbonyl, a pyrazylocarbonyl, an N-substituted carbamoyl, an N-substituted thiocarbamoyl, or carboxyl group; and R.sup.4 is a hydrogen atom, an alkyl, a pyridyl, a thienyl, a furyl, cyclohexyl, phenyl or a substituted phenyl group or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 6, 1989
    Date of Patent: February 5, 1991
    Assignee: Mitsui Toatsu Chemicals
    Inventors: Hiroyuki Yamashita, Makoto Odate, Hajime Iizuka, Hiroshi Kawazura, Yoshio Shiga, Hiroshi Namekawa
  • Patent number: 4983398
    Abstract: A therapeutically active solid unit dosage form comprising a carrier base material combined with a therapeutically active medicament and shaped and compressed to a solid unit dosage form having a controlled and sustained release pattern upon administration, the carrier base material comprising a mixture of one or more nonionic cellulose ethers and an alkali metal carboxylate, wherein at least one of the cellulose ethers is hydroxypropylmethylcellulose having a number average molecular weight of at least 50,000.
    Type: Grant
    Filed: December 15, 1988
    Date of Patent: January 8, 1991
    Assignee: Forest Laboratories, Inc.
    Inventors: Norman G. Gaylord, Ashok Nigalaye
  • Patent number: 4981694
    Abstract: Penicillin preparation for rectal administration containing benzylpenicillin and sodium lauryl sulphate in a hard gelatin capsule.
    Type: Grant
    Filed: July 7, 1989
    Date of Patent: January 1, 1991
    Assignee: Pharma-Vinci A/S
    Inventors: Nils V. Nielsen, Carsten Thordal, John E. Faber, Arne M. Pedersen
  • Patent number: 4971790
    Abstract: A composition of matter comprising a drug, a neutral hydrogel and an ionic hydrogel. The composition can be administered from a delivery system to a biological receptor over time.
    Type: Grant
    Filed: June 22, 1989
    Date of Patent: November 20, 1990
    Assignee: Alza Corporation
    Inventors: Paul R. Magruder, Patrick S. L. Wong, Felix Theeuwes, George V. Guittard
  • Patent number: 4968633
    Abstract: An allergological test for detecting an allergic condition, said test consisting in contacting the mucous membrane direct with the allergen or the anti-IgE antibody linked to a solid phase, so that a rapid in situ incubation is obtained of the allergen or of the anti-IgE antibody with the mucous membrane antibodies, and in the successive in vitro determination of the specific or total IgE through radioimmunological or immunoenzymatic procedures. Said testing procedure is carried out by employing a plastic material application device comprising one or more receptacles or housing in which some supports are inserted, such supports bearing allergens or anti-IgE antibodies linked to the supports themselves. Said testing procedure can also be employed for performing a particular test of specific challenging.
    Type: Grant
    Filed: May 26, 1987
    Date of Patent: November 6, 1990
    Inventor: Francesco Marcucci
  • Patent number: 4959217
    Abstract: This invention concerns novel, delayed/sustained release devices and compositions, including methods of their manufacture and use. The compositions include macromolecules, particularly polypeptide pharmaceuticals, and an initially partially-hydrated, non-biodegradable, hydrogel rate-limiting membrane.
    Type: Grant
    Filed: May 22, 1986
    Date of Patent: September 25, 1990
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Lynda M. Sanders, Abraham Domb
  • Patent number: 4954342
    Abstract: New compositions containing a calcitonin as the active ingredient are described which are suitable for the intrarectal administration as soft gelatin capsules or microenemas, wherein the active principle, optionally admixed with a stabilizer, is dissolved in a liquid vehicle consisting of: (a) at least 70% by weight of a polyethylene or a polypropylene glycol or a mixture of polyethylene or polypropylene glycols with different molecular weights, having the consistency of a homogeneous fluid at room temperature, and (b) less than 15% by weight of a buffer in a pH range of from 4.5 to 6.5, and optionally (c) less than 15% by weight of an alcohol of 2 to 6 carbon atoms containing two or more hydroxy groups.The new compositions, which do not contain any absorption aid, give calcitonin plasma levels comparable to a conventional intramuscular administration.
    Type: Grant
    Filed: September 26, 1988
    Date of Patent: September 4, 1990
    Assignee: Sclavo S.p.A.
    Inventors: Filippo Lattanzi, Riccardo Vanni
  • Patent number: 4952410
    Abstract: Pharmaceutical composition containing moxonidine (4-chloro-6-methoxy-2-methyl-5-(2-imidazolin-2-yl)aminopyrimidine) or its pharmaceutically acceptable salts and hydrochlorothiazide (6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide-1,1-dioxide ) and, if appropriate, triamterene (2,4,7-triamino-6-phenylpteridine).
    Type: Grant
    Filed: November 17, 1988
    Date of Patent: August 28, 1990
    Assignee: Beiersdorf AG
    Inventors: Ben Armah, Wolfgang Stenzel, Vera Planitz
  • Patent number: 4948588
    Abstract: A percutaneous absorption accelerator and a percutaneous absorbent preparation containing the same and, more particularly, a percutaneous absorption accelerator containing either derivatives of specific glycerols or polyglycerols and alcohols as effective components and a percutaneous absorbent preparation containing the percutaneous absorption accelerators and pharmaceutically effective components.
    Type: Grant
    Filed: June 2, 1989
    Date of Patent: August 14, 1990
    Assignee: Kao Corporation
    Inventors: Tetsuro Kamiya, Takeshi Inoue, Hidenori Yorozu, Yasuteru Eguchi, Kaoru Tsujii